Soligenix Inc. (SNGX) 1.4600 $SNGX
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Fri Feb 13, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax(TM)) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Wednesday, February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 39.30 (+1.05)
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Wed Feb 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated statistically significant efficacy of SGX943 in a mouse model of acute, lethal pneumonic melioidosis. The data was presented in an oral presentation at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Tuesday, February 10, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 39.30 (+1.05)
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Thu Feb 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 17th Annual BIO CEO Investor Conference in New York City, on Tuesday, February 10, 2015 at 1:30 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
XON: 39.30 (+1.05)
Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Mon Feb 02, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from two biodefense programs at the upcoming American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting on February 9-11, 2015 to be held at the Washington Marriott Wardman Park, 2660 Woodley Rd. NW.
XON: 39.30 (+1.05)
Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine
PR Newswire - Thu Jan 29, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating enhanced immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). VeloThrax(TM) employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM), has been previously demonstrated to enhance the thermostability of VeloThrax(TM), enabling distribution without cold chain requirements. In this work, the use of two adjuvants, aluminum hydroxide and Glycopyranoside Lipid A (GLA) in conjunction with ThermoVax(TM), was demonstrated to further enhance the immunogenicity and rapid action of the vaccine. The results were published online in the Journal of Pharmaceutical Sciences and are available at the following link: http://onlinelibrary.wiley.com/doi/10.1002/jp...26F.f01t03 .
XON: 39.30 (+1.05)
FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
PR Newswire - Wed Jan 07, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration (FDA).
XON: 39.30 (+1.05)
Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome
PR Newswire - Mon Jan 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that preliminary efficacy in an animal model of Macrophage Activation Syndrome (MAS) has been demonstrated with its SGX94 innate defense regulator (IDR) technology, significantly mitigating the pancytopenia characteristic of MAS.
XON: 39.30 (+1.05)
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 12.37 (unch), VTAE: 14.40 (+0.82), XNCR: 15.47 (-0.22)
Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data
PR Newswire - Mon Dec 29, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating that the combination of RiVax(TM) and VeloThrax(TM) induces protective immunity to both ricin toxin and anthrax toxin exposure. RiVax(TM) is the Company's candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. VeloThrax(TM) is the Company's candidate vaccine that employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine. The results were published online in Vaccine and are available at the following link: http://www.sciencedirect.com/science/article/...0X14015758.
XON: 39.30 (+1.05)
Soligenix Announces Closing of Public Offering of Units
PR Newswire - Wed Dec 24, 8:23AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.
Soligenix prices public offering at USD1.21 per unit
M2 - Mon Dec 22, 6:17AM CST
Biopharmaceutical company Soligenix (OTCBB:SNGX) disclosed on Friday that it has priced its public offering of 1,886,530 units at an offering price of USD1.21 per unit.
Soligenix prices offering
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 12:24PM CST
Soligenix Announces Pricing of Public Offering of Units
PR Newswire - Fri Dec 19, 7:24AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the pricing of its registered public offering of 1,886,530 units at an offering price of $1.21 per unit, with each unit consisting of one share of common stock and 0.6 of a warrant to purchase one share of common stock. Each whole warrant will be immediately exercisable to purchase one share of common stock at an exercise price of $1.48 per share and will expire on the fifth anniversary of its issuance. Soligenix expects to receive gross proceeds of approximately $2.3 million from this offering, before deducting underwriting discounts, commissions and other related expenses. The closing of the offering is expected to occur on December 24, 2014, subject to the satisfaction of customary closing conditions.
Soligenix Receives $617,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Thu Dec 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense announced today that it has recently received approximately $617,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer
PR Newswire - Wed Dec 10, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the appointment of Oreola Donini, PhD, as Senior Vice President & Chief Scientific Officer replacing Robert Brey, PhD, who is no longer employed with the Company. Dr. Donini previously held the position of Vice President, Preclinical Research and Development since joining Soligenix on August 15, 2013. She has more than 15 years experience in drug discovery and preclinical development with start-up biotechnology companies and has been instrumental in leading early stage development of several novel therapies into the clinic. Dr. Donini has worked previously with ESSA Pharma Inc., Inimex Pharmaceuticals Inc. and Kinetek Pharmaceuticals Inc., developing novel therapies for infectious disease, cancer and cancer supportive care.
Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board
PR Newswire - Mon Nov 17, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the Phase 3 clinical development of SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare class of non-Hodgkin's lymphoma (NHL).
Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma
PR Newswire - Mon Nov 10, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today its financial results for the third quarter and nine months ended September 30, 2014.
XON: 39.30 (+1.05)
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Revises Price Target Higher From $5.50 to $7.00
Marketwire - Wed Sep 24, 8:01AM CDT
Vista Partners announced today that it has updated coverage on Soligenix, Inc. (OTCBB: SNGX), based in Princeton, New Jersey, and revised its twelve-month price target higher from $5.50 to $7.00. Ross Silver, Principal Analyst at Vista Partners, stated, "The Company boasts a diverse pipeline with ten prospective drug candidates, including a Phase 3 ready asset slated to enter the clinic in early 2015. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. The Company has been awarded numerous government grants and entered into strategic agreements with two companies, Intrexon (~$1.9B mkt cap.) and SciClone (~$360M mkt cap). The main financial contributor has been the U.S. government. To date, the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. On top of the $7.1M financing completed in 2013, the Company has up to approximately $57 million in active government contracts and grant funding still available to support its associated research programs through 2018. The Company is in the process of petitioning and filling applications for a number of additional grants for further support of its programs with various funding agencies."
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
PR Newswire - Tue Sep 23, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the areas of formulation research, analytical method development, quality control (QC), and manufacturing. He has a proven track record in development, scale-up, and technology transfer supporting commercialization of vaccines and biologics, including Prevnar®, TetramuneTM, HibTITER®, Meningitec® Conjugate and meningitis B (bivalent rLP2086) Lipoprotein Subunit Vaccines.
MRK: 58.81 (-0.07), XON: 39.30 (+1.05)
Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax(TM) Vaccine
PR Newswire - Fri Sep 19, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID). The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax(TM), combined with the company's ricin toxin vaccine, Rivax(TM), as a medical countermeasure (MCM) to prevent the effects of ricin exposure.
XON: 39.30 (+1.05)
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Fri Feb 13, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax(TM)) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Wednesday, February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 39.30 (+1.05)
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Wed Feb 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated statistically significant efficacy of SGX943 in a mouse model of acute, lethal pneumonic melioidosis. The data was presented in an oral presentation at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Tuesday, February 10, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 39.30 (+1.05)
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Thu Feb 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 17th Annual BIO CEO Investor Conference in New York City, on Tuesday, February 10, 2015 at 1:30 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
XON: 39.30 (+1.05)
Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Mon Feb 02, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from two biodefense programs at the upcoming American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting on February 9-11, 2015 to be held at the Washington Marriott Wardman Park, 2660 Woodley Rd. NW.
XON: 39.30 (+1.05)
Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine
PR Newswire - Thu Jan 29, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating enhanced immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). VeloThrax(TM) employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM), has been previously demonstrated to enhance the thermostability of VeloThrax(TM), enabling distribution without cold chain requirements. In this work, the use of two adjuvants, aluminum hydroxide and Glycopyranoside Lipid A (GLA) in conjunction with ThermoVax(TM), was demonstrated to further enhance the immunogenicity and rapid action of the vaccine. The results were published online in the Journal of Pharmaceutical Sciences and are available at the following link: http://onlinelibrary.wiley.com/doi/10.1002/jp...26F.f01t03 .
XON: 39.30 (+1.05)
FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
PR Newswire - Wed Jan 07, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration (FDA).
XON: 39.30 (+1.05)
Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome
PR Newswire - Mon Jan 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that preliminary efficacy in an animal model of Macrophage Activation Syndrome (MAS) has been demonstrated with its SGX94 innate defense regulator (IDR) technology, significantly mitigating the pancytopenia characteristic of MAS.
XON: 39.30 (+1.05)
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 12.37 (unch), VTAE: 14.40 (+0.82), XNCR: 15.47 (-0.22)
Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data
PR Newswire - Mon Dec 29, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating that the combination of RiVax(TM) and VeloThrax(TM) induces protective immunity to both ricin toxin and anthrax toxin exposure. RiVax(TM) is the Company's candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. VeloThrax(TM) is the Company's candidate vaccine that employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine. The results were published online in Vaccine and are available at the following link: http://www.sciencedirect.com/science/article/...0X14015758.
XON: 39.30 (+1.05)
Soligenix Announces Closing of Public Offering of Units
PR Newswire - Wed Dec 24, 8:23AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.
Soligenix prices public offering at USD1.21 per unit
M2 - Mon Dec 22, 6:17AM CST
Biopharmaceutical company Soligenix (OTCBB:SNGX) disclosed on Friday that it has priced its public offering of 1,886,530 units at an offering price of USD1.21 per unit.
Soligenix prices offering
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 12:24PM CST
Soligenix Announces Pricing of Public Offering of Units
PR Newswire - Fri Dec 19, 7:24AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the pricing of its registered public offering of 1,886,530 units at an offering price of $1.21 per unit, with each unit consisting of one share of common stock and 0.6 of a warrant to purchase one share of common stock. Each whole warrant will be immediately exercisable to purchase one share of common stock at an exercise price of $1.48 per share and will expire on the fifth anniversary of its issuance. Soligenix expects to receive gross proceeds of approximately $2.3 million from this offering, before deducting underwriting discounts, commissions and other related expenses. The closing of the offering is expected to occur on December 24, 2014, subject to the satisfaction of customary closing conditions.
Soligenix Receives $617,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Thu Dec 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense announced today that it has recently received approximately $617,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer
PR Newswire - Wed Dec 10, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the appointment of Oreola Donini, PhD, as Senior Vice President & Chief Scientific Officer replacing Robert Brey, PhD, who is no longer employed with the Company. Dr. Donini previously held the position of Vice President, Preclinical Research and Development since joining Soligenix on August 15, 2013. She has more than 15 years experience in drug discovery and preclinical development with start-up biotechnology companies and has been instrumental in leading early stage development of several novel therapies into the clinic. Dr. Donini has worked previously with ESSA Pharma Inc., Inimex Pharmaceuticals Inc. and Kinetek Pharmaceuticals Inc., developing novel therapies for infectious disease, cancer and cancer supportive care.
Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board
PR Newswire - Mon Nov 17, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the Phase 3 clinical development of SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare class of non-Hodgkin's lymphoma (NHL).
Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma
PR Newswire - Mon Nov 10, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today its financial results for the third quarter and nine months ended September 30, 2014.
XON: 39.30 (+1.05)
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Revises Price Target Higher From $5.50 to $7.00
Marketwire - Wed Sep 24, 8:01AM CDT
Vista Partners announced today that it has updated coverage on Soligenix, Inc. (OTCBB: SNGX), based in Princeton, New Jersey, and revised its twelve-month price target higher from $5.50 to $7.00. Ross Silver, Principal Analyst at Vista Partners, stated, "The Company boasts a diverse pipeline with ten prospective drug candidates, including a Phase 3 ready asset slated to enter the clinic in early 2015. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. The Company has been awarded numerous government grants and entered into strategic agreements with two companies, Intrexon (~$1.9B mkt cap.) and SciClone (~$360M mkt cap). The main financial contributor has been the U.S. government. To date, the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. On top of the $7.1M financing completed in 2013, the Company has up to approximately $57 million in active government contracts and grant funding still available to support its associated research programs through 2018. The Company is in the process of petitioning and filling applications for a number of additional grants for further support of its programs with various funding agencies."
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
PR Newswire - Tue Sep 23, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the areas of formulation research, analytical method development, quality control (QC), and manufacturing. He has a proven track record in development, scale-up, and technology transfer supporting commercialization of vaccines and biologics, including Prevnar®, TetramuneTM, HibTITER®, Meningitec® Conjugate and meningitis B (bivalent rLP2086) Lipoprotein Subunit Vaccines.
MRK: 58.81 (-0.07), XON: 39.30 (+1.05)
Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax(TM) Vaccine
PR Newswire - Fri Sep 19, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID). The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax(TM), combined with the company's ricin toxin vaccine, Rivax(TM), as a medical countermeasure (MCM) to prevent the effects of ricin exposure.
XON: 39.30 (+1.05)
